Guggenheim Maintains Buy on Praxis Precision Medicine, Raises Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja maintains a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and raises the price target from $155 to $170.
August 14, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja maintains a Buy rating on Praxis Precision Medicine and raises the price target from $155 to $170.
The Buy rating and increased price target from a reputable analyst at Guggenheim is likely to boost investor confidence and positively impact the stock price of Praxis Precision Medicine in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100